|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.13 USD | +3.90% |
|
+5.45% | -36.61% |
Poseida Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 64.7 million compared to USD 130.49 million a year ago. Net loss was USD 123.43 million compared to USD 64 million a year ago.
Basic loss per share from continuing operations was USD 1.37 compared to USD 0.89 a year ago. Diluted loss per share from continuing operations was USD 1.37 compared to USD 0.89 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -36.61% | 206M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
POSEIDA THERAPEUTICS, INC. 
